# Adversarial re-verification verdict — granulosa_cell_tumour.md (pass 3)

## 1. DOSE LEAK
None. Only digits in the file: "mid-50s" (age, DeVita-grounded), "80 percent" (advanced-disease
mortality, verbatim DeVita), and "12th ed." (citation edition number). No mg, mg/m2, AUC, Gy,
cycle count, or numbered schedule anywhere.

## 2. UNGROUNDED / MISLABELLED CLAIMS
Re-checked every specific claim against DeVita lines ~178387-178410 (ovarian sex cord-stromal
tumor passage) plus lines 168277-168286 (testicular GCT — confirmed not what this sidecar cites).

Pass-2 residual issue is now fixed:
- "often unilateral" has been split into its own clause with its own explicit
  "(general oncology standard, not from DeVita's section on this disease)" tag, separate from the
  adjacent "favourable prognosis" tag. DeVita's GCT passage never mentions laterality, so the tag
  is correctly required and now correctly scoped — it no longer rides untagged inside a sentence
  that also contains DeVita-grounded content ("early-stage disease," ">80 percent... will die").
  The mortality statistic remains unqualified, as it should (verbatim DeVita).

Re-verified as accurate/matching DeVita, correctly attributed:
- Adult GCT mid-50s vs JGCT children/adolescents, both across age spectrum — matches.
- >80% of advanced-stage patients die — matches verbatim.
- "Most common malignant sex cord-stromal tumour" ranking claim — correctly tagged non-DeVita
  (DeVita only says sex cord-stromal tumors are <5% of ovarian malignancies and splits GCT/JGCT
  vs Sertoli-Leydig; no ranking statement).
- "Favourable prognosis for early-stage disease" — correctly tagged non-DeVita.
- Comprehensive staging surgery with salpingo-oophorectomy — correctly tagged non-DeVita.
- Lymphadenectomy can probably be omitted absent grossly enlarged nodes — matches verbatim,
  correctly attributed to DeVita.
- Fertility-preserving unilateral salpingo-oophorectomy for young women (general case) —
  correctly tagged non-DeVita; JGCT-specific fertility-preserving surgery sentence correctly
  attributed to DeVita ("Among young patients with JGCTs, fertility-preserving surgery should be
  instituted").
- BEP has demonstrable activity in GCT but responses not durable/long-lasting — matches verbatim,
  no dose given (correctly omitted).
- Serum inhibin A (occasionally inhibin B) aids preoperative diagnosis and recurrence monitoring
  — matches verbatim.
- No RT role for GCT in DeVita — correct, DeVita's passage does not mention radiotherapy for GCT.
- Everything else non-DeVita (endometrial sampling, aromatase inhibitors in relapse, AMH
  monitoring, MDT referral, indolent-biology/late-relapse framing, platinum-based combination for
  advanced disease) is explicitly tagged "general oncology standard, not from DeVita's section on
  this disease." No invented drug names, trial names, or statistics; no claim mis-attributed to
  DeVita.

Minor nuance (non-blocking, opposite-direction): the endometrial-sampling bullet is tagged
wholesale as non-DeVita, but DeVita's passage does state the underlying biology (GCT estrogen
"can induce neoplastic changes in the endometrium... atypical endometrial hyperplasia or
carcinoma") — only the specific recommended action ("sampling") is DeVita-silent. This
under-attributes rather than over-attributes DeVita, so it is not a fabrication/safety risk —
optional polish only.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology,
12th ed." — name only, no page numbers. PASS.

## 4. VERDICT
CLEAN (ready for R1 re-review). The sole pass-2 residual issue ("often unilateral" untagged) is
fixed with its own explicit tag. No dose leak, no fabricated/mis-attributed regimens, trials, or
statistics, citation format compliant. One low-severity, safe-direction nuance noted above
(endometrial-sampling bullet under-claims DeVita grounding) — optional, not blocking.
